Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage, aiming to address the substantial clinical and economic burden associated with knee osteoarthritis (OA). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing, and higher costs associated with some cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the United States, representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000, according to estimates highlighted in the announcement.
As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology, and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. The company’s Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.
Gelrin C is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. This news matters because it highlights a potential shift toward more accessible and cost-effective regenerative therapies for a common and debilitating condition, offering possible savings for the healthcare system and improved outcomes for patients.
For more information, readers can view the full article at https://ibn.fm/yPKU2 and stay updated with the latest news on RGNT at the company’s newsroom at https://ibn.fm/RGNT.
